Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Gains from Investment Securities (2018 - 2025)

iBio (IBIO) has disclosed Gains from Investment Securities for 12 consecutive years, with $53000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 26.39% to $53000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $206000.0, a 2323.53% increase, with the full-year FY2025 number at $299000.0, down 36.79% from a year prior.
  • Gains from Investment Securities was $53000.0 for Q3 2025 at iBio, down from $78000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $814000.0 in Q3 2022 to a low of $8500.0 in Q4 2024.
  • A 5-year average of $102613.5 and a median of $71000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 825.0% in 2022, then plummeted 91.89% in 2023.
  • iBio's Gains from Investment Securities stood at $34880.0 in 2021, then skyrocketed by 2233.72% to $814000.0 in 2022, then tumbled by 91.77% to $67000.0 in 2023, then plummeted by 87.31% to $8500.0 in 2024, then surged by 523.53% to $53000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Gains from Investment Securities are $53000.0 (Q3 2025), $78000.0 (Q2 2025), and $75000.0 (Q1 2025).